Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
ContraFect Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'ContraFect Corporation - Product Pipeline Review - 2016', provides an overview of the ContraFect Corporation's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by ContraFect Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of ContraFect Corporation - The report provides overview of ContraFect Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses ContraFect Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features ContraFect Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate ContraFect Corporation's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for ContraFect Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding ContraFect Corporation's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 ContraFect Corporation Snapshot 5 ContraFect Corporation Overview 5 Key Information 5 Key Facts 5 ContraFect Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 ContraFect Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 ContraFect Corporation - Pipeline Products Glance 11 ContraFect Corporation - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 ContraFect Corporation - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 ContraFect Corporation - Drug Profiles 14 CF-301 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 CF-401 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CF-402 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CF-403 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CF-404 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibody 1 for Influenza 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CF-302 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CF-303 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CF-304 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CF-305 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CF-306 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 CF-307 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 CF-308 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 CF-309 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ContraFect Corporation - Pipeline Analysis 29 ContraFect Corporation - Pipeline Products by Target 29 ContraFect Corporation - Pipeline Products by Route of Administration 30 ContraFect Corporation - Pipeline Products by Molecule Type 31 ContraFect Corporation - Pipeline Products by Mechanism of Action 32 ContraFect Corporation - Recent Pipeline Updates 33 ContraFect Corporation - Dormant Projects 36 ContraFect Corporation - Locations And Subsidiaries 37 Head Office 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
ContraFect Corporation, Key Information 5 ContraFect Corporation, Key Facts 5 ContraFect Corporation - Pipeline by Indication, 2016 7 ContraFect Corporation - Pipeline by Stage of Development, 2016 9 ContraFect Corporation - Monotherapy Products in Pipeline, 2016 10 ContraFect Corporation - Phase I, 2016 11 ContraFect Corporation - Preclinical, 2016 12 ContraFect Corporation - Discovery, 2016 13 ContraFect Corporation - Pipeline by Target, 2016 29 ContraFect Corporation - Pipeline by Route of Administration, 2016 30 ContraFect Corporation - Pipeline by Molecule Type, 2016 31 ContraFect Corporation - Pipeline Products by Mechanism of Action, 2016 32 ContraFect Corporation - Recent Pipeline Updates, 2016 33 ContraFect Corporation - Dormant Developmental Projects,2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.